List your company

SFA-002

Drug discovery and biotech · by SFA Therapeutics, Inc.

Oral, once-daily deuterated short-chain fatty acid tablet for plaque psoriasis (mild-to-severe), currently in Phase 2 clinical development.

Visit website

What it does

Oral, once-daily deuterated short-chain fatty acid tablet for plaque psoriasis (mild-to-severe), currently in Phase 2 clinical development. Investigational therapy not approved by the FDA.

  • Immune tolerance therapy for plaque psoriasis
  • Combination therapy for pancreatic cancer
  • Therapy for chronic liver disease to hepatocellular carcinoma
  • Therapies for rheumatoid arthritis and inflammatory bowel disease
Category
Drug discovery and biotech
Built for
Healthcare and life sciences
Users
Patients with psoriasis, Patients with autoimmune diseases, Patients with certain cancers
Public API
Not offered

Not yet disclosed: deployment options, platforms, languages and support channels.

Pricing

Pricing isn't published

SFA Therapeutics, Inc. doesn't list prices publicly. Ask them for a quote.

Security and compliance

No security details published yet

SFA Therapeutics, Inc. hasn't published certifications or security practices for SFA-002 that we could find. Ask their team for audit reports.

Reviews

No reviews yet

Reviews come from people who use SFA-002 at work. Share how your team uses it to help other buyers decide.

Write a review

Alternatives

  • ITO™ Platform

    by 1910

    Cloud-based end-to-end platform integrating massive multimodal data, frontier AI models, and high-throughput lab automation to deliver small and large molecule drug candidates f...

  • AI Agents

    by Enjamb Labs

    Agentic orchestration that coordinates specialized agents across evidence, trial design, statistical programming, and regulatory writing inside one auditable workspace.

  • Integrations

    by Invert

    Pre-built connectivity to every instrument, historian, ELN/LIMS, and enterprise data store that matters in bioprocess.

  • Numerion Labs Drug Discovery Platform

    by Numerion Labs

    AI-driven drug-hunting superplatform that uses a universal chemistry foundation model (COSMOS), a hyper-scalable enumerator (APEX), and expert optimization algorithms (EXPO) to...

  • Quinn

    Scientific evidence synthesis service delivering structured evidence packages for target, indication, biomarker, and trial design decisions on named drug assets.

  • Precision medicine

    by Parallel Bio

    Maps of human biology for personalized insights and patient stratification in ways never previously possible.

Is this your product?

Claim it to keep details accurate and submit evidence for the next ranking review.

Claim SFA-002